Loading...
•
Jun 30, 2023
Adicet Bio Q2 2023 Earnings Report
Reported financial results and operational highlights for the second quarter ended June 30, 2023.
Key Takeaways
Adicet Bio reported a net loss of $32.4 million for the second quarter of 2023, with research and development expenses increasing to $28.4 million. The company's cash and cash equivalents totaled $205.5 million as of June 30, 2023, expected to fund operations into the first half of 2025. Clinical development continues with ADI-001, ADI-925 and ADI-270.
Announced encouraging safety and efficacy data from the Phase 1 study of ADI-001 for relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL).
On track to report a clinical update for ADI-001 in the second half of 2024.
Plan to file Investigational New Drug Application (IND) for ADI-925 in H2 2023 and ADI-270 in H1 2024.
Strong balance sheet with $205.5 million in cash and cash equivalents as of June 30, 2023.
Forward Guidance
Adicet Bio is focused on advancing its pipeline of allogeneic gamma delta T cell therapies for cancer. The company anticipates several milestones, including clinical updates and IND submissions, while maintaining a sufficient cash position to fund operations into the first half of 2025.
Positive Outlook
- Clinical update for ADI-001 is expected in the second half of 2024.
- IND for ADI-925 is planned for submission in H2 2023.
- IND for ADI-270 is planned for submission in H1 2024.
- ADI-001 program is planned to transition into a potentially pivotal Phase 2 study in 2024.
- Cash and cash equivalents are expected to fund operating expenses into the first half of 2025.
Challenges Ahead
- The effect of global economic conditions and public health emergencies on Adicet’s business and financial results.
- Positive results from a preclinical or clinical study may not be predictive of the results of future studies.
- Clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...